Ticker

No recent analyst price targets found for PHRRF.

Latest News for PHRRF

PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new strategic initiative to pursue Health Canada approval for generic semaglutide in Canada and, subject to regulatory approval, its commercialization.

Newsfile Corp • Feb 2, 2026
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategic initiative to expand its PharmaPatch™ microneedle patch platform into GLP-1…

Newsfile Corp • Jan 14, 2026
PharmaTher CEO Publishes Letter to Shareholders

Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders.

Newsfile Corp • Jan 2, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for PHRRF.

No Senate trades found for PHRRF.

No House trades found for PHRRF.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top